Lymphoma Medicines in India: Imported Options for Hodgkin and Non-Hodgkin Types
Hodgkin, B-cell and T-cell lymphoma: how the groups differ
A pathologist names the lymphoma by looking at the biopsy under the microscope and by staining it for surface markers such as CD20, CD19 or CD30. That label matters more than the word "lymphoma" itself, because almost every imported medicine below is approved for one or two named subtypes only.
| Group | Common subtypes | What Indian series found | Medicines on this page |
|---|---|---|---|
| Fast-growing B-cell NHL | Diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma | DLBCL was the top NHL subtype at CMC Vellore [4] and in Bihar, where it made up 58% of NHL [5] | Columvi, Epkinly, Zynlonta, Monjuvi, Minjuvi, Zuberitamab |
| Slow-growing B-cell NHL | Follicular lymphoma (FL), small lymphocytic lymphoma (SLL) | The Bihar team found follicular lymphoma less common in India than in Western reports [5] | Epkinly (FL); Jaypirca, Lisaftoclax, Sonrotoclax (SLL) |
| Mantle cell lymphoma | MCL | Also reported as less frequent in India than in the West [5] | Jaypirca, Sonrotoclax |
| Hodgkin lymphoma | Classical Hodgkin lymphoma (cHL) | 21.3% of 5,115 lymphomas at CMC Vellore; mixed cellularity was the leading subtype [4] | Opdivo |
| T-cell lymphoma | Peripheral T-cell lymphoma (PTCL), mycosis fungoides and Sézary syndrome (CTCL), T-lymphoblastic lymphoma | T/NK-cell types formed 20.2% of NHL at Vellore, more than Western series show [4] | Folotyn, Beleodaq, Zeprumetostat, Istodax, Poteligeo, Targretin, Zolinza, Atriance |
How many people in India get lymphoma
For 2024, IARC's GLOBOCAN estimates list 41,973 new non-Hodgkin lymphoma cases in India, ranked 11th among all cancers, and 23,769 deaths from it. Hodgkin lymphoma added 9,973 new cases and 2,685 deaths [1]. Taken together that is 41,973 + 9,973 = 51,946 new cases and 23,769 + 2,685 = 26,454 deaths in a single year.
Across the world, the same programme counts 562,793 new NHL cases [2] and 84,495 new Hodgkin cases [3]. India's portion is therefore 41,973 ÷ 562,793 = 7.5% of NHL and 9,973 ÷ 84,495 = 11.8% of Hodgkin lymphoma.
The subtype mix in India is not the same as in Europe or the USA. In the CMC Vellore series of 5,115 lymphomas, peripheral T-cell and NK-cell lymphomas were more frequent than in Western data, and about one NHL in three (32.8%) started outside the lymph nodes, most often in the gut [4]. A Patna study of 518 cases noted that T-lymphoblastic and anaplastic large-cell lymphomas are seen more often in India [5].
What Indian treatment studies report
- DLBCL responds well to rituximab-based treatment. Among 580 DLBCL patients at NRS Medical College, Kolkata (median age 55), 75% received R-CHOP and two-year overall survival was 81.4%. Complete response was 73% in the germinal centre type but 43% in the activated B-cell type [7].
- Older patients do better on the full regimen when fit. At Tata Memorial Centre, 218 people aged 60 or over with DLBCL were reviewed: two-year progression-free survival was 79.1% with R-CHOP against 49.6% with the etoposide-based R-CEOP substitute [8].
- Biosimilar rituximab gave similar results. A 29-centre Indian study of 1,365 DLBCL patients on two rituximab biosimilars reported two-year progression-free survival of 69% and overall survival of 78.7% [9].
- Risk score shapes the outlook. In 214 adults with NHL treated at a Tata Memorial unit in Guwahati, five-year overall survival was 47.84% overall, 62.09% with a low-risk IPI score and 25.17% with a high-risk score [10].
- Hodgkin lymphoma is highly curable. At Kidwai Memorial Institute, Bengaluru, 200 adults and teenagers with classical Hodgkin lymphoma (median age 28) had an 84.5% complete response rate and 84.1% overall survival at six years, even though 62.5% came with advanced stage [11]. In children with early-stage disease, the InPOG-HL-15-01 study across 27 Indian centres reported five-year overall survival of 95.5% [12].
- Childhood B-cell NHL needs strong supportive care. In the InPOG-NHL-16-01 study of 191 children, Burkitt lymphoma made up 69.6% of cases, and treatment-related deaths (14.3%) were a major reason for lost cures [13].
Matching a relapse to a medicine
Most medicines listed here are meant for lymphoma that has come back or did not respond to earlier treatment. The table shows how the label wording lines up with each situation; the hematologist makes the final call.
| Situation | Medicines on this page |
|---|---|
| DLBCL that has failed two or more earlier lines | Columvi, Epkinly, Zynlonta |
| DLBCL relapsed, transplant not possible | Monjuvi or Minjuvi, each given with lenalidomide |
| Newly diagnosed CD20-positive DLBCL | Zuberitamab with CHOP (China approval) |
| Follicular lymphoma that has relapsed | Epkinly (with lenalidomide and rituximab, or alone after two lines) |
| Mantle cell lymphoma after a BTK inhibitor | Jaypirca, Sonrotoclax |
| Classical Hodgkin lymphoma, stage III–IV at diagnosis or after transplant | Opdivo |
| PTCL that has relapsed | Folotyn, Beleodaq, Zeprumetostat |
| Skin T-cell lymphoma after systemic treatment | Istodax, Poteligeo, Targretin, Zolinza |
India also has its own CAR-T cell therapy. Talicabtagene autoleucel, the first humanised CD19 CAR-T approved in the country, was given to 145 people with relapsed or refractory B-cell NHL in a 56-centre Indian study; at 12 months, 63% were alive and 47% had no progression [14]. Ask your centre whether it is an option before choosing an imported medicine.
Imported lymphoma medicines by type
All 18 medicines below are prescription-only. Tap a type to filter. Each card opens the full medicine page with dosage, storage and safety details.
.webp)

















Compare all 18 lymphoma medicines
| Medicine | Generic name | Lymphoma type | Form | Approved by |
|---|---|---|---|---|
| Columvi | glofitamab | Large B-cell (DLBCL) | IV infusion | US FDA |
| Epkinly | epcoritamab | Large B-cell (DLBCL), Follicular (FL) | Subcutaneous injection | US FDA |
| Zynlonta | loncastuximab tesirine | Large B-cell (DLBCL) | IV infusion | US FDA |
| Monjuvi | tafasitamab | Large B-cell (DLBCL) | IV infusion | US FDA |
| Minjuvi | tafasitamab | Large B-cell (DLBCL) | IV infusion | EMA (Europe) |
| Zuberitamab | zuberitamab | Large B-cell (DLBCL) | IV infusion | China NMPA |
| Jaypirca | pirtobrutinib | Mantle cell (MCL), Small lymphocytic (SLL) | Tablet | US FDA |
| Sonrotoclax | sonrotoclax | Mantle cell (MCL), Small lymphocytic (SLL) | Tablet | US FDA (as Beqalzi), China NMPA |
| Lisaftoclax | lisaftoclax | Small lymphocytic (SLL) | Tablet | China NMPA |
| Opdivo | nivolumab | Hodgkin (cHL) | IV infusion | US FDA |
| Folotyn | pralatrexate | Peripheral T-cell (PTCL) | IV injection | US FDA |
| Beleodaq | belinostat | Peripheral T-cell (PTCL) | IV infusion | US FDA |
| Zeprumetostat | zeprumetostat | Peripheral T-cell (PTCL) | Tablet | China NMPA |
| Istodax | romidepsin | Skin T-cell (CTCL) | IV infusion | US FDA |
| Poteligeo | mogamulizumab | Skin T-cell (CTCL) | IV infusion | US FDA |
| Targretin | bexarotene | Skin T-cell (CTCL) | Capsule | US FDA |
| Zolinza | vorinostat | Skin T-cell (CTCL) | Capsule | US FDA |
| Atriance | nelarabine | T-lymphoblastic (T-LBL) | IV infusion | US FDA (as Arranon) |
Papers your doctor will ask for
| Document | Why it matters |
|---|---|
| Biopsy with immunohistochemistry | Names the subtype and shows markers such as CD20, CD19 or CD30 |
| PET-CT or CT scan report | Gives the stage, and later shows whether the lymphoma has responded or come back |
| Bone marrow report | Shows whether the lymphoma has reached the marrow, which changes the stage |
| List of past treatments | Many approvals depend on how many lines were given before and whether a BTK inhibitor, rituximab or a transplant was used |
| Recent blood tests | Blood counts and liver and kidney function help the doctor judge whether a medicine can be started safely |
Import permit, hospital supply and cost support
Each import is made for one patient by name. Our pharmacist fills in Form 12A on behalf of the patient, who submits it to CDSCO; the regulator's answer is a Form 12B permit valid for this one shipment. See the Form 12A / 12B permit page for the papers involved.
The antibodies here, such as Columvi, Epkinly, Zynlonta, Monjuvi and Poteligeo, are given under hospital supervision, so we usually route them to the treating hospital's pharmacy in a temperature-controlled pack. Our hospital delivery page explains that process. Tablets and capsules such as Jaypirca, Targretin and Zolinza are usually taken at home.
Lymphoma care can stretch over many cycles. If cost is a worry, look at the manufacturer schemes and charity routes listed under patient support and access programs.
How to get these lymphoma medicines in India
Prescription
Your doctor prescribes the medicine.
Share documents
Send the prescription and latest reports through Online Order.
Import paperwork
Our team checks the source and the import permissions.
Delivery
Delivered with the right storage, including cold chain.
Read How to Order and Indian import regulations. We also serve patients in Delhi NCR, Bangalore, Chennai, Mumbai, Kolkata, Hyderabad and Pune.
Has your doctor prescribed one of these medicines?
Share the prescription and we will guide you on availability and next steps.
Read more about lymphoma
- Diffuse large B-cell lymphoma: a guide
- FDA approves Jaypirca for previously untreated CLL and SLL
- What is cancer? Types, causes, symptoms, stages and treatment
- All Hematology medicines
References
- IARC Global Cancer Observatory. GLOBOCAN 2024 – India fact sheet (September 2026). https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf
- IARC Global Cancer Observatory. GLOBOCAN 2024 – Non-Hodgkin lymphoma fact sheet (July 2026). https://gco.iarc.who.int/media/globocan/factsheets/cancers/34-non-hodgkin-lymphoma-fact-sheet.pdf
- IARC Global Cancer Observatory. GLOBOCAN 2024 – Hodgkin lymphoma fact sheet (July 2026). https://gco.iarc.who.int/media/globocan/factsheets/cancers/33-hodgkin-lymphoma-fact-sheet.pdf
- Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases. Leuk Lymphoma. 2013;54(5):1004-11. https://pubmed.ncbi.nlm.nih.gov/22971239/
- Lisa M et al. Distribution of lymphoma subtypes in Bihar – analysis of 518 cases using the WHO classification of lymphoid tumors (2017). J Lab Physicians. 2020;12(2):103-110. https://pubmed.ncbi.nlm.nih.gov/32905403/
- Burad DK et al. Peripheral T-cell lymphoma: frequency and distribution in a tertiary referral center in South India. Indian J Pathol Microbiol. 2012;55(4):429-32. https://pubmed.ncbi.nlm.nih.gov/23455774/
- Dolai TK et al. Diffuse large B-cell lymphoma – experience from a tertiary care hospital in Eastern India. Indian J Hematol Blood Transfus. 2025;41(4):822-827. https://pubmed.ncbi.nlm.nih.gov/41084583/
- Jobanputra K et al. Diffuse large B-cell lymphoma in the elderly: real-world outcomes from a developing country. Clin Lymphoma Myeloma Leuk. 2022;22(10):e898-e906. https://pubmed.ncbi.nlm.nih.gov/35810145/
- Nair R et al. Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. Front Oncol. 2023;13:1248723. https://pubmed.ncbi.nlm.nih.gov/37854680/
- Vinodhini M et al. Outcome of non-Hodgkin's lymphoma in adults – real world experience from a cancer centre in North-East India. Indian J Hematol Blood Transfus. 2026;42(3):797-808. https://pubmed.ncbi.nlm.nih.gov/42040712/
- Jacob LA et al. Clinical profile and outcome of adult classical Hodgkin's lymphoma: real world single centre experience. Indian J Hematol Blood Transfus. 2024;40(3):392-399. https://pubmed.ncbi.nlm.nih.gov/39011262/
- Mahajan A et al. Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience. Pediatr Blood Cancer. 2021;68(10):e29219. https://pubmed.ncbi.nlm.nih.gov/34291860/
- Rahiman EA et al. Outcome and prognostic factors in childhood B non-Hodgkin lymphoma from India (InPOG-NHL-16-01 study). Pediatr Hematol Oncol. 2022;39(5):391-405. https://pubmed.ncbi.nlm.nih.gov/34978257/
- Karulkar A et al. Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies: multicenter real-world evidence. Blood Cancer J. 2026;16(1):177. https://pubmed.ncbi.nlm.nih.gov/42463637/
- US FDA prescribing information for each US-approved medicine (DailyMed). https://dailymed.nlm.nih.gov/dailymed/
This page gives general information only and does not replace medical advice. All medicines listed are prescription-only and must be used under a qualified doctor.